✍ Scribed by Saarinen, Ulla M. ;Hovi, Liisa ;Riikonen, Pekka ;Pihkala, Jaana ;Juvonen, Eeva
No coin nor oath required. For personal study only.
Twenty children 1–17 (median, 5.5) years of age received GM‐CSF during chemotherapy‐induced neutropenia at the dose of 5 μg/kg/day, continued until the absolute neutrophil count (ANC) exceeded 500 × 10^6^/liter. Twelve children with solid tumors received GM‐CSF after courses of conventional chemotherapy (VP‐16 + ifosfamide or “6 in 1”). One course followed by GM‐CSF was compared to identical courses without GM‐CSF in the same patients. Eight children with recurrent/poor risk malignancies received GM‐CSF after marrow‐ablative therapy and autologous bone marrow transplantation (ABMT). Their engraftment data were compared to matched historical controls. In both groups GM‐CSF accelerated myeloid recovery, which was preceded by the appearance of immature myeloid elements in bone marrow. The ANC levels of 200, 500, and 1,000 × 10^6^/liter were exceeded 2, 3 (P<0.05), and 6 (P<0.005) days earlier with GM‐CSF in the conventional chemotherapy group, and 6, 10 (P<0.05), and 9 days earlier in the ABMT group, as compared to the controls. All adverse effects observed were mild, including skin rashes, nasal stuffiness, general achiness, nausea, and fever. We conclude that GM‐CSF is well tolerated in children and accelerates myeloid recovery in chemotherapy‐induced neutropenia. © 1992 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Combinations of low dosages of purified recombinant human (rh) macrophagecolony stimulating factor (M-CSF; also termed CSF-1) and rh granulocyte-colony stimulating factor (G-CSF) were compared alone and in combination for their influence on the cycling rates and numbers of bone marrow and splenic gr
Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8.
Tumor metastasis is the primary cause of death for cancer patients. The metastatic cascade requires successful tumor cell invasion into and through vascular and parenchymal barriers. We have shown that autocrine motility factor (AMF, autotaxin) and the insulin-like growth factors (IGFs) induce tumor